Compare Medpace Holdings Inc (MEDP) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Marathon Petroleum Corp — how do they compare? Medpace Holdings Inc trades at $532.89 (market cap $15.08B), while Marathon Petroleum Corp trades at $317.66 (market cap $92.05B). The key difference: Marathon Petroleum Corp is far larger — about 6.1× Medpace Holdings Inc's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MPC | |
|---|---|---|
Market Cap | $15.08B | $92.05B |
Sector | Technology | Energy |
52-Week High | $620.59 | $315.31 |
52-Week Low | $308.88 | $158.59 |
Enterprise Value | $14.55B | $124.23B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Marathon Petroleum (MPC) trades at $317.00, up 1.41% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 20.58, P/S of 0.7, and ROE of 27.92%, supported by recent earnings beats in Q4 2025 and Q1 2026. Cash flow trends indicate operational strength with $8.25B from operations in 2025, while refining margins drive profitability, as highlighted in recent Zacks reports (July 2026).
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $292.70, though risks include volatile energy markets and rising debt-to-asset ratios. The stock's proximity to resistance at $317 suggests potential consolidation, but sustained refining advantages and institutional support offer upside potential for investors focused on energy sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
